Treatment of hemophilia B requires frequent infusions of Factor IX (FIX) to prophylaxe against bleeding episodes. Hemophilia B management would benefit from a FIX protein with an extended half-life. A recombinant fusion protein (rFIXFc) containing a single FIX molecule attached to the Fc region of IgG was administered intravenously and found to have an extended half-life, when compared to recombinant FIX (rFIX) in normal mice, rats, monkeys, and FIXdeficient mice and dogs. Recombinant FIXFc protein concentration was determined in all species, and rFIXFc activity was measured in FIX-deficient animals. The half-life of rFIXFc was approximately 3 to 4-fold longer than that of rFIX in all species. In contrast, in mice in which the neonatal Fc receptor (FcRn) was deleted, the half life of rFIXFc was similar to rFIX, confirming the increased circulatory time was due to protection of the rFIXFc via the Fc/FcRn interaction.
Introduction
Hemophilia B is an X chromosome-linked bleeding disorder resulting from a deficiency in functional Factor IX (FIX) and affects 1 in every 25,000 to 30,000 males. 1, 2 Severe hemophilia B patients (FIX < 1 International Units [IU]/dL) in particular suffer from repeated bleeding episodes resulting in hemophilic arthropathy, and other sequelae. 2, 3 Like hemophilia A (Factor VIII deficiency), conventional treatment for hemophilia B has been on-demand, ie, patients are administered concentrates of the deficient factor when hemorrhage occurs or prior to a surgical procedure. 3 Alternatively, replacement therapy can be given in regular intervals prophylactically to maintain FIX levels > 1%, thereby converting a severe phenotype into one that is milder and to potentially prevent life-threatening hemorrhages and musculo-articular bleeding events. [3] [4] [5] [6] When treating bleeding episodes on-demand or in the surgical setting, several infusions of FIX may be required to avoid peaks and troughs and maintain minimum coagulation factor levels for a sufficient duration. Similarly, in patients being treated on prophylactic regimens, two to three injections per week are usually required to achieve the necessary FIX plasma levels. This can be attributed, in part, to the relatively short half-lives of approximately 18 hr of currently available products. 7 In hemophilia B, twice-or thrice-weekly dosing with 40-100 IU/kg of FIX parents, and possibly decreasing repeated dosing in the treatment of episodic bleeds or in surgical settings. Recombinant Factor IX-Fc fusion protein (rFIXFc) contains a single molecule of FIX recombinantly attached to the constant region (Fc) of immunoglobulin G (IgG) and was developed to address the unmet medical need for a long-acting FIX product. The presence of the Fc domain enables the fusion protein to bind to the neonatal Fc receptor (FcRn), a heterodimer of an MHC class I-like-protein heavy chain with β -2-microglobulin (β2m). 9 FcRn serves a critical role in IgG homeostasis by protecting the Fc-containing molecules from catabolism. 9, 10 We report here the enhanced pharmacokinetics and pharmacodynamics of rFIXFc compared to commercially available recombinant FIX.
Materials and methods

Cloning, expression, and purification of rFIXFc
All molecular biology procedures were performed following standard techniques. 11 The coding sequences for human FIX, the Fc region of the human IgG1 (hinge and CH 2 and CH 3 domains) and PC5 were obtained by PCR from human liver mRNA, human lymphocyte cDNA, and human liver mRNA, respectively, and cloned into mammalian expression vectors.
HEK-293H cells (Invitrogen, Carlsbad, CA) were stably transfected with expression cassettes for both FIXFc (native FIX coding sequence fused to the Fc region with no intervening linker) and were infused with rFIXFc intravenously. These experiments were performed at the FOBRL.
All cynomolgus monkeys underwent pre-study physical exams; all animals were determined to be in good health prior to dosing.
All animal studies were conducted in compliance with Institutional Animal Care and Use Committee-approved protocols at their respective institutions.
Administration of FIX preparations and blood sampling
Pharmacodynamic studies in FIX-deficient mice
Single and repeat dose studies were performed in FIX-deficient mice to evaluate clotting activity of rFIXFc compared to rFIX. In both studies, FIX-deficient mice received 219 IU/kg rFIXFc or 200 IU/kg rFIX by intravenous administration. In the repeat-dose study, the same dose 
Coagulation testing
Factor IX activity assay An automated Factor IX activity assay was performed using the MLA Electra 1600C FIX-deficient dogs were infused intravenously with 140 IU/kg rFIXFc and blood samples were drawn to measure the whole blood clotting time (WBCT) as described.
Pharmacokinetic data analyses and statistical methods
Pharmacokinetic analysis was performed using non-compartmental modeling with 
Results
Biochemical characterization of rFIXFc
Recombinant FIXFc samples were analyzed by a number of biochemical methods ( Table   1) per molecule, comparable to rFIX which was found to contain 11.6 ± 0.52 Gla per molecule, consistent with literature values of 11.5 Gla per molecule. 21 Peptide mapping confirmed the gamma-carboxylation pattern to be similar to rFIX, with 10 of the 12 sites fully occupied, and the residues primarily at position 36 and 40 being under-gamma-carboxylated, which has been shown to have no effect on activity.
14 In addition to gamma-carboxylation and propeptide processing, a number of other posttranslational modifications were assessed for rFIXFc and compared to rFIX (BeneFIX ® ) and
. In general, rFIXFc was found to be comparable to rFIX, with respect to Ser 158 phosphorylation and Tyr 155 sulfation ( Table 1) . N-linked glycosylation fingerprints indicated that the FIX-derived glycans are not fully sialylated, similar to rFIX (data not shown).
O-linked glycosylation isoforms in the first EGF domain were the same as rFIX but present at different relative ratios (data not shown). Recombinant FIXFc possessed a greater degree of β -hydroxylation of Asp 64 than rFIX or pdFIX. The levels of activated FIX were measured in all 3
proteins, and found to be significantly lower in rFIXFc than either rFIX or pdFIX.
The specific activity of rFIXFc ranged from 4.28 ± 0.52 to 6.12 ± 0.28 IU/nmol for protein lots that had undergone a 3-column purification process, corresponding to 43.8 ± 5.4 to 62.7 ± 2.87 IU/mg based on the Factor IX activity assay using a WHO calibration standard. For some of the earlier in vivo experiments, the specific activity of rFIXFc was lower prior to optimization of the purification process. This however did not have an effect on pharmacokinetic properties of rFIXFc (data not shown).
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Coagulation activity in FIX-deficient mice
Fifteen minutes after administration, rFIXFc and rFIX corrected the circulating levels to 1.47 ± 0.32 IU/mL and 2.28 ± 1.01 IU/mL, respectively. At 48 hr, the rFIXFc clotting activity remained high at 0.27 ± 0.15 IU/mL, while clotting activity with rFIX had decreased substantially to 0.07 ± 0.03 IU/mL. Clotting activity for the rFIX-treated mice was undetectable at timepoints later than 48 hr after dosing, while rFIXFc-treated mice continued to retain measurable activity, remaining at 0.10 ± 0.04 IU/mL at 96 hr (Figure 2) .
In whole blood samples, 15 min after administration, normal clotting was observed in all mice given rFIXFc or rFIX (Figure 3 ). Blood clotting times in all of the rFIX-treated animals returned to baseline by 72 hr, whereas blood from all of the rFIXFc-treated mice still clotted throughout this time. Clotting activity in blood from rFIXFc-treated mice returned to baseline by 144 hr in all animals, twice the time observed for the rFIX-treated mice.
In repeat-dose experiments in FIX-deficient mice comparing the activity of rFIXFc and rFIX, 15 min after the first dose, rFIXFc and rFIX demonstrated comparable clotting activity, of 1.96 ± 0.23 IU/mL and 1.09 ± 0.14 IU/mL, respectively. By 96 hr, clotting activity was measurable in all 6 rFIXFc-treated mice (0.12 ± 0.08 IU/mL) but not in rFIX-treated mice (the limit of detection of the assay was approximately 0.01 IU/mL). Similar results were obtained over the next 2 doses, measuring comparable peak activities 15 min after dosing for rFIXFc and rFIX (2.34 ± 0.73 v. 1.94 ± 0.35 IU/ml, respectively, after the second dose, and 2.12 ± 0.20 v.
1.69 ± 0.70 IU/ml, respectively, after the third dose) but only detecting clotting activity in the rFIXFc-treated mice after 96 hours (0.12 ± 0.017 and 0.12 ± 0.034 IU/ml after the second and third dose, respectively) with one exception, in that 1 of 5 animals dosed with rFIX exhibited detectable clotting activity (0.08 IU/ml) at 4 days after the second dose.
Recombinant FIXFc protein levels were also determined by ELISA analysis. In general, the pharmacokinetic profile appears to reflect the activity levels found in the single-dose experiment, possibly with a slight accumulation of drug as the peak levels were found to increase after the first, second, and third doses from 24.05 ± 7.02 to 36.85 ± 10.96 and to 38.19 ± 9.49 µg/mL, respectively. Similarly, the trough levels increased from 1.60 ± 0.60 to 1.88 ± 0.72 to 3.22 ± 0.74 µg/mL, respectively. Based on the specific activity of this lot of rFIXFc (43.8 IU/mg) and the ELISA data (μg/mL), calculated plasma clotting activity level was determined (IU/mL) and compared to measured clotting activity. The results of this comparison are shown in 
Pharmacokinetics in mice and rats
In rats, the t ½ of rFIXFc was 34. 
strain, the t ½ of rFIXFc was 53.0 ± 6.6 hr in contrast to rFIX, which had a t ½ of 14.2 ± 2.9 hr in these same mice.
Pharmacokinetics and pharmacodynamics in FIX-deficient dogs
Clotting activity was measured for all time points and demonstrated that the activity versus time curves are similar for the 2 animals (Figure 5a ), declining in a biphasic manner characteristic of Factor IX. 22 The C max at 15 minutes post-infusion was found to be 1.028 IU/mL in dog I08; the earliest time point for which clotting activity was determined for dog I03 was 1 hour, at which time the level was 0.681 IU/mL compared to 0.466 IU/mL for I08. At 144 hours, clotting activity was still detectable, and found to be 0.027 and 0.022 IU/mL for dog I03 and I08, respectively, after which the levels fell below the limit of detection of approximately 0.01 IU/mL at 168 hr. Terminal half-lives of 37.7 hr and 38.8 hr were calculated for dogs I03 and I08, respectively, using the best fit of the data from the 12 to 144 hour time points.
A sandwich ELISA was used to measure the concentration of intact rFIXFc in the Hemophilic B dog plasma samples (Figure 5b) . The plasma concentration vs time curves were similar for the 2 animals, declining in a biphasic manner and consistent with the activity data (compare Figures 5a and 5b) . Terminal half-lives of 37.5 hr and 57.4 hr were calculated for dogs I03 and I08, respectively, using the best fit of the data from the 24 hr to 144 hr time points.
Baseline whole blood clotting time (WBCT) is 8-12 min for normal dogs and > 60 min for FIX-deficient dogs. Immediately upon administration of rFIXFc, clotting time was corrected from pre-dose levels to approximately normal levels of 13.5 and 11.5 min for dog I03 and I08, respectively. Whole blood clotting activity remained corrected to approximately normal levels 
Pharmacokinetics in non-human primates
The pharmacokinetics of rFIXFc were evaluated at 3 dose levels (0.5, 2, and 10 mg/kg, approximately 25, 100, and 500 IU/kg), demonstrating consistent levels within each group and showing dose-proportionality between groups with average maximum plasma concentrations (C max ) of 6.05 μg/mL, 24.54 ± 1.59 μg/mL, and 129.82 ± 3.45 μg/mL, respectively (Figure 6 ).
At 168 hr, rFIXFc protein levels were 0.13, 0.37 ± 0.03, and 1.59 ± 0.07 μ g/mL, respectively, for the 3 doses. The area under the time vs concentration curve also demonstrated doseproportionality, with AUC of 164, 530 ± 79, and 2654 ± 415 μ g•hr/mL, at the 0.5, 2, and 10 mg/kg levels, respectively. Pharmacokinetic analysis determined the t ½ to be 47.0 hr (n = 2), 47.8 ± 2 hr (n = 3), and 47.0 ± 13.3 hr (n = 3), respectively, for the 3 dose groups.
Discussion
Recombinant FIXFc, a fusion protein comprised of a single molecule of FIX fused to the Fc domain of human immunoglobulin G1 (IgG1), was developed to address the short half-life of currently available FIX products used to treat patients with hemophilia B. We have demonstrated that the elimination half-life of rFIXFc was consistently 3-to 4-fold longer than rFIX across species ( The mechanism for the extension of half-life is based on the ability of the Fc domain of the fusion protein to bind to the neonatal Fc receptor, FcRn, at acidic pH (< 6.5) but not at physiological pH (7.4). 9, 10 FcRn is a heterodimer comprised of a major histocompatability complex (MHC)-class-I-related heavy chain and the β 2-microglobulin light chain that is found complexed to all MHC class I molecules. In addition to the pharmacokinetics of rFIXFc, we have examined the pharmacodynamics in two FIX-deficient species. In FIX-deficient mice, rFIXFc and rFIX, administered at approximately the same dose, corrected the clotting deficiency to comparable levels; however the effect of rFIXFc was significantly prolonged to at least 96 hr after infusion. This trough activity of rFIXFc corresponds to approximately 10% of its normal clotting activity. Current prophylactic FIX replacement therapy for patients with hemophilia B aims to maintain plasma levels of 1-2% normal clotting activity. 29 The whole blood clotting time (WBCT) assay is an ex vivo test that measures the ability of whole blood to form a clot and is an alternate confirmatory test for the restoration of clotting activity. In response to infusion with rFIXFc, the WBCT of the hemophilic dogs was corrected from > 60 min to approximately the normal range of 10-12 min and remained in this range for 144 hr before returning to pre-dose levels at 168 hr. In a direct comparison in FIX-deficient mice, although both rFIXFc and rFIX led to whole blood clotting immediately upon infusion,
only rFIXFc-treated animals demonstrated sustained clotting activity.
FIX is a complex protein that contains a number of functional domains which undergo extensive post-translational modifications. 21, 30 One of the essential post-translational modifications for FIX activity is gamma-carboxylation of the first 12 glutamic acids in the Gla domain by vitamin K-dependent γ -glutamyl carboxylase. This modification facilitates the binding of FIX to phospholipid membranes and, thus, is critical to its function. FIX that is not gamma-carboxylated is not functional, and hence gamma-carboxylation is a rate-limiting step during FIX production. 31, 32 HEK-293 cells have proven to be an efficient expression system since they are capable of high-level expression and produce post-translational modifications, in particular, for gamma-carboxylation superior to CHO or BHK cells. 33 HEK-293 cells are of human, rather than rodent, origin and therefore may result in posttranslational modifications more representative of human proteins. For these reasons, we chose to express rFIXFc in HEK-293 cells. The Gla content of rFIXFc was found to be comparable to that of rFIX by both amino acid analysis and peptide mapping. The rFIXFc protein was extensively characterized and found
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Although one or more of these characteristics have been proposed to be linked to the lower recovery of rFIX as compared to pdFIX, it is unclear from the current data if this will be the case for rFIXFc as well, or if fusion with Fc will alter the recovery. One difference we have found is in the level of activated Factor IX, which is 10-fold lower in rFIXFc preparations as compared to rFIX or pdFIX.
Another key difference observed between rFIXFc and other FIX products has been in the specific activity as assessed by aPTT-based assays. As noted above, the specific activity of rFIXFc ranges from 4.41 ± 0.22 to 6.12 ± 0.28 IU/nmol for protein lots that had undergone 3-column purification, corresponding to 45.2 ± 2.25 to 62.7 ± 2.87 IU/mg, with more recent lots having a specific activity of approximately 60 IU/mg (unpublished data). In comparison, rFIX has a specific activity in aPTT-based assays of approximately 260 IU/mg, or 12.1 IU/nmol. Due to the presence of the Fc domain in rFIXFc, the more appropriate comparison for specific activity is on a molar basis, where rFIXFc is approximately 2-fold lower than rFIX. Extensive biochemical characterization of rFIXFc indicated that the difference in specific activity was not due to any deficiency in critical post-translational modifications, such as gamma-carboxylation or propeptide processing.
Further studies have been performed examining the interactions of rFIXFc in the context of the tenase complex on a variety of phospholipid sources, including cephalin, synthetic phospholipid vesicles, and nonactivated and activated platelets and found them to be comparable to rFIX (Toby et al, unpublished data). Though the exact mechanistic basis for the difference in specific activity remains under investigation, this difference is unlikely to be therapeutically relevant, as rFIXFc is dosed on an IU basis, and such a dosing regimen has been found to result in similar initial blood levels of activity as compared to rFIX in experiments performed in FIXdeficient mice.
Traditionally, Fc fusion proteins have been made as dimers, with respect to the effector molecule and the Fc region. 34 Previously we have generated a novel fusion protein which has a monomeric effector molecule conjugated to the Fc domain. 35 We had also demonstrated that such a configuration of EpoFc enhanced its pharmacodynamic and pharmacokinetic properties.
Similarly, we have found that the FIXFc monomer has enhanced pharmacokinetic properties as compared to the FIXFc dimer, in particular, in significantly higher C max and AUC. 36 In conclusion, data from these studies indicate that rFIXFc has enhanced pharmacokinetic parameters compared to rFIX, particularly in its terminal half-life. Clinical studies with this longacting rFIXFc coagulation factor are in progress to investigate its potential to reduce the frequency of injections in patients receiving routine (prophylactic) doses of factor replacement.
Whether rFIXFc can confer prolonged protection from bleeding following each dose of factor, decrease the overall units of factor needed to treat bleeding episodes, or maintain adequate hemostasis during surgical procedures with fewer injections are of considerable clinical interest. 
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Table 1. Biochemical characterization of rFIXFc
Posttranslational modifications and other analyses of rFIXFc, rFIX, and pdFIX were assessed in a variety of assays as described in the methods. Numbers in parentheses taken from published values. FIX activity data was also obtained from FIX-deficient mice (n = 4 / timepoint) and FIXdeficient dogs (n = 2) and terminal half-life based on activity calculated (listed in parentheses).
*Represents published values of t 1/2 for recombinant FIX, based on activity data. 22, 23 † Represents published values of t 1/2 for recombinant FIX, based on ELISA data. 23 For personal use only. on October 31, 2017. by guest www.bloodjournal.org From
